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MaHypertrophic cardiomyopathy (HCM) is a common inherited heart disease with diverse phenotypic and genetic expres-
sion, clinical presentation, and natural history. HCM has been recognized for 55 years, but recently substantial advances
in diagnosis and treatment options have evolved, as well as increased recognition of the disease in clinical practice.
Nevertheless, most genetically and clinically affected individuals probably remain undiagnosed, largely free from
disease-related complications, although HCM may progress along 1 or more of its major disease pathways (i.e.,
arrhythmic sudden death risk; progressive heart failure [HF] due to dynamic left ventricular [LV] outﬂow obstruction or
due to systolic dysfunction in the absence of obstruction; or atrial ﬁbrillation with risk of stroke). Effective treatments are
available for each adverse HCM complication, including implantable cardioverter-deﬁbrillators (ICDs) for sudden death
prevention, heart transplantation for end-stage failure, surgical myectomy (or selectively, alcohol septal ablation) to
alleviate HF symptoms by abolishing outﬂow obstruction, and catheter-based procedures to control atrial ﬁbrillation.
These and other strategies have now resulted in a low disease-related mortality rate of <1%/year. Therefore, HCM has
emerged from an era of misunderstanding, stigma, and pessimism, experiencing vast changes in its clinical proﬁle, and
acquiring an effective and diverse management armamentarium. These advances have changed its natural history, with
prevention of sudden death and reversal of HF, thereby restoring quality of life with extended (if not normal) longevity
for most patients, and transforming HCM into a contemporary treatable cardiovascular disease. (J Am Coll Cardiol
2014;64:83–99) © 2014 by the American College of Cardiology Foundation.M ore than 50 years have elapsed since themodern pathological description of hy-pertrophic cardiomyopathy (HCM) by
Teare in 1958 (1), followed shortly thereafter by the
ﬁrst detailed clinical reports from Dr. Eugene Braun-
wald and colleagues at the National Institutes of
Health (Bethesda, Maryland) in the early 1960s (2).
For much of the early years, HCM was considered
a rare, interesting, and perhaps odd (if not exotic)
disease, with high mortality and little effective or
safe treatment interventions. In particular, measures
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plex genetic disease, were unavailable to young
patients for decades. In a very early (1962) paper
that deﬁned left ventricular (LV) outﬂow tract
obstruction in HCM, Dr. Braunwald wrote: “At this
time, we are aware of no method of management
that can speciﬁcally and favorably inﬂuence the
course of a patient” (3).
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last decade (4–13), changes in the clinical proﬁle,
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ABBR EV I A T I ON S
AND ACRONYMS
ACC = American College of
Cardiology
AF = atrial ﬁbrillation
AHA = American Heart
Association
CAD = coronary artery disease
CMR = cardiovascular magnetic
resonance
ECG = electrocardiography
HCM = hypertrophic
cardiomyopathy
HF = heart failure
ICD = implantable
cardioverter-deﬁbrillator
LGE = late gadolinium
enhancement
LV = left ventricle
LVH = left ventricular
hypertrophy
SD = sudden death
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84of the full diversity of the disease spectrum,
which is now recognized as associated with a
relatively low adverse event rate (14–22); 2)
deﬁnition of the molecular basis of the
disease, with the opportunity for family
screening and identiﬁcation of relatives
not at risk for developing HCM, as well as
affected family members without clinical ev-
idence of disease (12,23–26); 3) introduction
of implantable cardioverter-deﬁbrillators
(ICDs) for prevention of SD (27–31); 4) devel-
opment of a more reliable stratiﬁcation
model, expanding recognition and apprecia-
tion of the highest-risk patients who will most
likely beneﬁt from ICDs (8,32–34); 5) pene-
tration of advanced imaging into HCM prac-
tice with high-resolution and tomographic
cardiovascular magnetic resonance (CMR)
imaging (Fig. 1), complementary to echocar-
diography, with improved diagnosis and
identiﬁcation of novel at-risk subgroups,
expanding the scope of risk stratiﬁcation(9,17,19,35); 6) advances in operative (myectomy)
techniques, resulting in low-risk surgery that is highly
effective in abolishing outﬂow obstruction and heart
failure (HF) symptoms (10,13,36); 7) introduction of
nonsurgical alternatives to myectomy for selected
patients, such as percutaneous alcohol septal abla-
tion (37); 8) recognition of the impact of patient age
in dictating clinical course and management de-
cisions (38); 9) publication of comprehensive guide-
lines offering concise and speciﬁc recommendations
to the practicing community for diagnosis and man-
agement (39,40); 10) advances in refractory HF
treatment, including transplantation (18); 11) recog-
nizing the signiﬁcant cardiovascular mortality beneﬁt
attributable to contemporary treatment options
(27,28,41); and 12) evolution in the perception of HCM
to a disease deserving of a more optimistic outlook,
compatible with extended longevity for most pa-
tients and affording them with a measure of reas-
surance (42).
These advances for patients with HCM support this
State-of-the-Art review, which is designed to provide
the cardiovascular community with an opportunity to
appreciate the important current approaches to this
complex disease. This is a clinically relevant, patient
care-related discussion formulated around contem-
porary HCM practice patterns, assembled by the ef-
forts of 6 expert cardiologists with established
dedication to HCM and care of these patients. The
presentation is structured around 7 major areas:
epidemiology; genetics and genetic testing; clinical
diagnosis with imaging; natural history and impact oftherapy; risk stratiﬁcation and prevention of SD; HF
management, septal reduction therapy, and trans-
plantation; and the role and signiﬁcance of atrial
ﬁbrillation (AF).
HCM remains a challenging disease, character-
ized by a heterogeneous clinical proﬁle and con-
siderable unpredictability in its natural history,
with clinical decisions often made without absolute
certainty on the basis of incomplete data.
EPIDEMIOLOGY
Although once considered rare, HCM is now more
appropriately regarded as the most common inheri-
ted cardiac disease. A number of population studies
estimate the prevalence of HCM in the general po-
pulation to be at least 1 in 500, with the extrapola-
tion that 700,000 Americans are affected by this
disease (43).
HCM is a global disease, reported in >50 countries
on all continents, including the most populous na-
tions of India and China (7). Consequently, HCM is
known to occur in a variety of races and ethnic groups
(44), as well as equally in both sexes and with a
generally similar clinical, phenotypic, and genetic
expression (45).
Paradoxically, the estimated prevalence of HCM in
the general population seems inconsistent with the
persistent perception in cardiovascular practice that
it is a distinctly uncommon disease. This apparent
discrepancy strongly suggests that most affected in-
dividuals are not diagnosed clinically, probably
achieving advanced longevity without HCM-related
symptoms. Therefore, clinicians assess only a small
fraction of the overall HCM population (likened to
the “tip of the iceberg”), which often includes pa-
tients who are diagnosed only because of symptoms
or clinical events (46). Fortuitous diagnosis of HCM
during routine clinical or family screening and eval-
uation is increasing due to unexpected ﬁndings on
electrocardiography (ECG) or advanced imaging (47).
GENETICS
GENERAL PRINCIPLES. It has been almost 25 years
since the seminal work by the Seidman laboratory and
others identiﬁed the ﬁrst sarcomere gene mutations
that cause HCM, bringing this genetic disease into the
modern era of molecular investigation (25). HCM is
inherited with an autosomal dominant Mendelian
pattern, variable expressivity, and age-related (and
incomplete) penetrance (12,25,48–50). Offspring of an
affected individual have a 50% probability of inher-
iting a mutation and risk for the disease; alterna-
tively, sporadic cases may be due to de novo
FIGURE 1 Cardiovascular Magnetic Resonance Images Demonstrate Diversity of the Hypertrophic Cardiomyopathy Phenotype
(A) Asymmetric hypertrophy of ventricular septum (VS), sparing the left ventricular (LV) free wall. (B) Focal hypertrophy sharply conﬁned to
basal anterior septum (arrows). (C) Thin-walled apical aneurysm (arrowheads) with muscular mid-ventricular apposition of hypertrophied
septum and LV wall (asterisks), and distinct proximal (P) and distal (D) chambers. Adapted with permission from Maron et al. (19).
(D) Extensive, transmural late gadolinium enhancement involving ventricular septum (arrows). (E) Massive thickening (i.e., 33 mm) conﬁned
largely to anterolateral LV wall, greatly underestimated by echocardiography (arrowheads). Adapted with permission from Maron et al (9).
(F) Genotype positive-phenotype negative HCM family member with 3 myocardial crypts penetrating thickness of basal inferior wall (arrows).
Adapted with permission from Maron et al. (55). LA ¼ left atrium; RA ¼ right atrium; RV ¼ right ventricle.
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85mutations present in the proband, but which
are absent in the parents (12,25,48–50).
To date, a large number of genetic studies have
established that HCM is caused by mutations in 11 or
more genes encoding thick and thin contractile
myoﬁlament protein components of the sarcomere,
or adjacent Z-disc, which are expressed primarily
or exclusively in the heart (12,25,48–50) (Fig. 2).
Approximately, 70% of successfully genotyped pa-
tients are found to have mutations in the 2 most
common genes, beta-myosin heavy chain and
myosin-binding protein C, whereas several other
genes are much less common, accounting for <5% of
patients (Fig. 2).
The genetic heterogeneity of HCM has proved
daunting, now with more than 1,500 individual mu-
tations (90% missense mutations) identiﬁed among
the known genes, most of which appear to be
“private” and unique to individual families (12,25).
This vast genetic heterogeneity of HCM, perhaps
more than any other factor, has limited the role of
mutational analysis in predicting prognosis (orphenotypic expression) for individual patients
(Central Illustration).
GENETIC TESTING RESULTS. Although initially
conﬁned to research settings, numerous commercial
laboratories and academic centers now offer com-
prehensive (usually fee-for-service) genetic testing
panels using rapid and automated DNA-sequencing
to identify HCM-causing mutations and provide a
molecular diagnosis (12). Despite early optimism that
“malignant” or “benign” mutations would be identi-
ﬁable among patient populations (25), more recent
clinical genetic studies have shown that using single
nucleotide sarcomere mutations to judge prognosis
or predict outcome is unreliable for individual pa-
tients (4,12,40). Therefore, genetic testing in HCM
does not inﬂuence treatment strategies and specif-
ically does not identify high-risk patients who may
beneﬁt from ICD therapy (4,12,27,28,40).
Cl in ica l ut i l i ty of genet ic test ing . The most
compelling reason to speciﬁcally consider genetic
testing in clinical practice is to identify family mem-
bers affected by HCM, but without left ventricular
FIGURE 2 Genetics and Family Screening Strategies in HCM
Cardiac sarcomere showing the location of known HCM disease-causing genes. Prevalence for each of the 11 genes derived from studies in
unrelated HCM probands with positive genotyping are shown in parentheses. Not shown are genes previously linked to HCM, but with lesser
evidence for pathogenicity: a-myosin heavy chain, titin, muscle LIM protein, telethonin, vincalin/metavinculin, junctophilin 2. Adapted with
permission from Maron and Maron (4).
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86hypertrophy (LVH), who nevertheless may be at risk
for developing this disease (Central Illustration).
Notably, in practical terms, the genetic testing
screening strategy requires successful identiﬁcation
of a pathogenic (disease-causing) sarcomere mutation
in a clinically expressed HCM proband. However, the
likelihood that a pathogenic mutation will be found in
the proband is only 35% overall (although somewhat
higher with positive family history) (4,12,48–50).
When a pathogenic mutation is identiﬁed in a family
member, the genetic status of all other relatives can
be interrogated; those who did not inherit the genetic
abnormality found in the proband have a very low
risk for developing the disease (4,12).
HCM GENOTYPE WITHOUT LVH. Relatives identiﬁed
with pathogenic mutations but without evidence of
the disease phenotype comprise a newHCM subgroup,
designated as genotype positive-phenotype negative
(24,40,51,52) (Central Illustration). Such individuals
demonstrate the principle that any absolute LV wall
thickness is compatible with HCM. The precise risk of
eventually developing LVH in this group remains
uncertain, largely due to the relatively short periodof time that commercial genetic testing has been
widely accessible. Nevertheless, although phenotypic
conversion is probably common, it is also possible that
some relatives may never develop hypertrophy (i.e.,
incomplete penetrance). However, ECG abnormalities
and subclinical diastolic dysfunction can be nonin-
vasive markers for future development of LVH in
gene carriers. In addition, despite the absence of
LVH, gene carriers may show various LV morphologic
abnormalities, including ﬁbrosis imaged by contrast
CMR, collagen biomarkers, mitral leaﬂet elongation,
and blood-ﬁlled crypts (4,53–55). If identiﬁed in a
relative of a HCM patient, these markers suggest
affected status, and emphasize the importance of
formal genotyping to achieve a deﬁnitive HCM diag-
nosis, as well as close follow-up for detecting devel-
opment of clinical disease with LVH. There is no
compelling evidence that genetically affected rela-
tives without LVH are at increased risk of SD
(12,51,52,56), and Bethesda Conference #36 consensus
recommendations do not exclude genotype positive-
phenotype negative individuals from competitive
sports (57).
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CENTRAL ILLUSTRATION Clinical Testing and Management Strategies in HCM
*Patients without LV outﬂow tract gradient (<30 mm Hg) at rest should also undergo stress (exercise) echocardiography. Not shown here, on
initial evaluation, all HCM patients undergo sudden death risk stratiﬁcation (refer to Fig. 5). †Generally regarded as $30 mm Hg outﬂow
gradient, but $50 mm Hg when septal reduction intervention is considered (i.e., septal myectomy; alcohol ablation). ‡No or trivial (<30 mm
Hg) outﬂow gradient at rest and with exercise. §No data on beneﬁt of pharmacologic therapy, although beta-blockers are often administered
prophylactically in clinical practice. kObstructive: usually, beta-blockers or possibly calcium channel antagonists (verapamil), or disopyramide.
Nonobstructive: beta-blockers, calcium channel antagonists, and possibly diuretics administered judiciously. ¶Screening targets relatives
without clinical evidence of HCM phenotype. #Could differentiate hypertrophic cardiomyopathy (HCM) from other causes of left ventricular
hypertrophy (LVH), including patients with history of systemic hypertension, or highly trained athletes.
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87DEFINING PATHOGENICITY. Mutations are assigned
pathogenic (or likely pathogenic) status on a proba-
bilistic basis—not necessarily as a deﬁnitive yes or no
(12,58)—using the preponderance of evidence avail-
able from a variety of criteria, including previous re-
ports that a given mutation has caused HCM in other
families (12). If the genetic test in the proband is
negative for a sarcomere mutation, or alternatively a
novel DNA sequence variant for which pathogenicity
is unresolved (i.e., “variant of unknown signiﬁ-
cance”) is reported, then this testing strategy cannot
be applied to determine whether other relatives are
genetically affected. Increasing numbers of ambig-
uous variants identiﬁed with comprehensive DNA
next-generation sequencing could further confuseinterpretation of genetic screening results, under-
scoring the challenges for translating complex mo-
lecular science to patient care in HCM (12). Although
not widely recognized by clinicians, there is a possi-
bility, in up to 10% of probands, that the classiﬁcation
of any variant can be re-interpreted over time, as new
information becomes accessible (59), causing the
reassessment of genetic testing implications for a
family.
DIFFERENTIAL DIAGNOSIS. Notably, genetic testing
has the unique potential to clarify diagnosis in
some patients with metabolic storage diseases
(i.e., PRKAG2, Fabry disease, LAMP2 cardiomyo-
pathy [Danon disease]), which differ from sarcomeric
HCM with respect to pathophysiology, natural
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88history and management, but share similar clinical
expression and the pattern of LVH (Central
Illustration). For example, genetic testing is crucial
for diagnosis of LAMP2, which has a lethal natural
history (survival uncommon at >25 years of age) that
requires early recognition and usually interven-
tion with heart transplantation (60). Genetic testing
is also crucial for Fabry disease, which has a differ-
ent treatment algorithm, with primary enzyme
replacement.
CLINICAL FAMILY SCREENING. Screening for HCM is
universally recommended for families. The ﬁrst op-
tion for assessment of family members is usually
clinical screening with imaging tests (echocardiogra-
phy and CMR) and ECG (Central Illustration). This
strategy is usually initiated during adolescence, the
time at which the development of LVH most often
occurs in HCM (4,6,12,23,26,39,40). Therefore, for
relatives, echocardiographic screening most often
begins at approximately 12 years of age, continuing
thereafter at 12- to 18-month intervals, until full
physical maturity is achieved between 18 and 20
years of age (23,39,40). Because of the rare possibility
of adult onset hypertrophy and phenotypic conver-
sion later in life between 20 and 50 years of age,
further serial imaging at approximately 5-year in-
tervals may be appropriate (26,61). It would be ad-
vantageous to consider screening with CMR,
particularly if the 12-lead ECG is abnormal, because in
some patients, segmental areas of LVH may be
identiﬁable only with high-resolution tomographic
CMR (9).
Furthermore, all HCM patients and relatives
should have access to some form of genetic coun-
seling, including discussion of testing results, risks
and/or beneﬁts, and options (12). Certiﬁed genetic
counselors play an important role in collecting data
to facilitate cosegregation studies and clarifying
pathogenicity of mutations, as well as organizing
family discussions to mitigate psychosocial impact
of inheriting a potentially deleterious disorder (56).
In the United States, many HCM patients are evalu-
ated in settings where the multidisciplinary model
incorporating cardiologists and counselors into one
program can be difﬁcult to create.
CLINICAL DIAGNOSIS AND HCM PHENOTYPE:
CONTEMPORARY IMAGING
HCM WITH LVH. Clinical diagnosis of HCM requires
conﬁrmation with cardiac imaging of phenotypic
expression, that is, an unexplained increase in LV
wall thickness ($15 mm in adults) associated with
a nondilated LV chamber (4,9,57,62). Lesser degreesof wall thickness (i.e., 13 to 14 mm) can also be
diagnostic of HCM, particularly when identiﬁed in
family members (4,9). Since the early 1970s, echo-
cardiography has been the mainstay for imaging the
HCM phenotype (63), and it remains the initial test
for patients due to its portability, widespread access,
and reliability in quantifying dynamic outﬂow tract
gradients (62).
More recently, CMR has emerged as a powerful
complementary tool due to its unique strengths of
tomographic imaging and enhanced spatial resolu-
tion, which affords better characterization of the
complex HCM phenotype. Speciﬁcally, CMR provides
an opportunity to provide more precise LV wall
thickness measurements and improved risk stratiﬁ-
cation by imaging myocardial scars (i.e., late gado-
linium enhancement) (35) (Fig. 1). In selected
patients, CMR may be the sole method for reliably
conﬁrming the HCM phenotype and diagnosis, par-
ticularly when increased wall thickness is conﬁned to
speciﬁc areas of the LV chamber, such as the antero-
lateral free wall and apex (9,64). Underestimation of
LV wall thickness by echocardiography (with respect
to CMR) may have management implications (9),
particularly in patients with massive LVH, which is an
independent SD risk factor in HCM (65).
Furthermore, CMR provides a more complete
interrogation of HCM morphology, including right
ventricular hypertrophy, high-risk LV apical aneu-
rysms with regional scarring, and abnormalities that
may contribute to subaortic obstruction (i.e., elon-
gated mitral valves, aberrant papillary muscles, and
accessory muscle bundles), as well as anomalous
insertion of anterolateral papillary muscle directly
into the mitral valve, producing mid-cavitary
muscular obstruction (4,9,17,19,22,66). CMR also
may allow differentiation of apical HCM from LV
noncompaction.
Although a wide range in maximal LV wall thick-
nesses up to >50 mm are consistent with HCM (9,62),
an important minority of patients (10% to 20%) show
relatively mild degrees of LVH evident in localized
segments of the chamber (9,64), and with normal
CMR-calculated LV mass (67). This underscores the
principle that increased LV mass is not a prerequisite
for a HCM diagnosis.
Virtually any asymmetric pattern of LVH can be
observed in phenotypically expressed HCM, with
maximum wall thickening found at virtually any
location (9,62), but most commonly at the conﬂuence
of the anterior septum and contiguous anterior free
wall (9). Speciﬁc patterns of LVH do not predict
outcome, although mild localized wall thickening is
generally associated with lower risk, independent of
FIGURE 3 Pyramid Proﬁle of Risk Stratiﬁcation Model Currently Used to Identify Patients at the Highest SD Risk Who May Be Candidates
for ICDs and SD Prevention
Major and minor risk markers appear in boxes at the left. At right are the results of ICD therapy in 730 children, adolescents, and adults
assembled from 2 registry studies (28,29). *Extensive LGE is a novel primary risk marker that can also be used as an arbitrator when con-
ventional risk assessment is ambiguous. †SD events are uncommon after 60 years of age, even with conventional risk factors (38). BP ¼ blood
pressure; CAD ¼ coronary artery disease; EF ¼ ejection fraction; ICD ¼ implantable cardioverter-deﬁbrillator; LV ¼ left ventricular; LGE ¼ late
gadolinium enhancement; LVH ¼ left ventricular hypertrophy; NSVT ¼ nonsustained ventricular tachycardia; SD ¼ sudden death; VT/VF ¼
ventricular tachycardia/ventricular ﬁbrillation; y ¼ years.
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89its location (65). The absence of hyperdynamic systolic
function, systolic anterior motion of the mitral valve,
ormyocardial scarring on CMRdoes not exclude aHCM
diagnosis. Extrinsic factors, such as obesity, may in-
ﬂuence primary phenotypic expression of HCM
(including LV mass) and HF symptoms (68).
CLINICAL COURSE AND NATURAL HISTORY
HCM is perhaps unique among cardiovascular dis-
eases by virtue of its potential for identiﬁcation,
clinical presentation, and progression during all
phases of life, from infancy to advanced age. This
long period of observation can itself impede complete
understanding of the natural history of HCM over the
many decades of life.
In the last 10 to 15 years, considerable clarity has
emerged regarding HCM from large retrospective
and/or observational cohort studies in a number
of institutions and multicenter populations. It is
evident that HCM is frequently compatible with
normal life expectancy, often without functional
disability or disease-related events, nor the necessity
for major therapeutic interventions (4,14,39,40,42).
This is a source of reassurance to many patientsregarding their prognosis. Not uncommonly, HCM
patients survive to 70, 80, and even >90 years of
age (69), often with no or mild symptoms, reaching
statistical longevity similar to that of age and
sex-matched general populations. This underscores
the principle that mortality in most HCM patients
is ultimately attributable to non-HCM and non-
cardiovascular causes.
Nevertheless, subgroups at risk for important dis-
ease complications and premature death reside
within the overall HCM population (Fig. 3). Patients
may be situated in, or progress to, speciﬁc adverse
pathways, with the natural history of their disease
punctuated by events that may be the target of spe-
ciﬁc treatment strategies: 1) risk of SD; 2) progressive
HF with exertional dyspnea and functional limitation
(with or without chest pain); or 3) paroxysmal or
chronic AF.
Reported HCM-related mortality risk has under-
gone substantial revision over time. For example,
25 years ago, HCM was regarded as a particularly
high-risk disease with an annual mortality of 4% to
6%, based largely on patient populations from a
few highly selected tertiary referral centers of a
previous era (70–72). Patient selection bias in such
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90programs effectively overestimated the risk of HCM
(73), contributing to the reputation of this dis-
ease as one with a grim prognosis and little
expectation for longevity, a myth that may still
persist today.
In the 1990s, reports from patient cohorts char-
acterized by less selectivity, adjusted expected HCM
mortality rates to about 1.5%/year (14). However, by
utilizing contemporary and aggressive treatment
interventions (particularly the ICD and heart trans-
plantation), mortality in adult patients has further
decreased to about 0.5% per year (41), thereby
transforming HCM into a treatable condition with
low disease-related mortality. Furthermore, because
the SD rate has decreased due to increasing pene-
tration of ICDs into HCM practice, death due to HF
is emerging as the predominant mode of demise.
Patient age itself is an important determinant of
HCM-related event rates and clinical course. For
example, SD events are most common in young
patients <30 years of age (4–6,8,15), but paradoxi-
cally, SD is very uncommon in patients of more
advanced ages (>60 years) (38), even among those
with acknowledged risk factors. In this age group,
HCM appears to have a more benign expression and a
lower risk status by virtue of decades of stability and
survival. Both sexes have similar SD risk, although
women are diagnosed later in life, often with more
advanced HF symptoms (45).
However, the unpredictability of the HCM disease
process requires regular (usually annual) surveil-
lance to monitor potential clinical and/or risk pro-
ﬁle changes. The most advantageous outcomes
may derive from engagement in multidisciplinary-
dedicated HCM centers, in which all management
options (and expert operators) are available within
the same institution (74,75). Such treatment oppor-
tunities, which have dramatically changed the
outlook for many HCM patients, may not yet be
readily available (or even a realistic aspiration) for
patients in many parts of the world. For example, the
vast number of HCM patients in the most populous
countries (i.e., India and China) do not have access to
robust personal medical insurance infrastructures
that permit full penetration of innovative but
expensive treatment strategies (e.g., ICDs).
RISK STRATIFICATION
Since the initial description of HCM, including the ﬁrst
contemporary report of an autopsy-based series (1),
SD has been recognized as a devastating but
unpredictable disease consequence; therefore, it
becomes a crucial consideration in advising patientsabout their prognosis. Although a highly visible dis-
ease feature, SD is nevertheless conﬁned to a rela-
tively small subset of patients within the broad
disease spectrum, most commonly young people
through mid-life. SD usually occurs without premon-
itory warning signs or symptoms, but not uncom-
monly is associated with vigorous physical activity
(4,8,39,40).
Recognition that the mechanism of SD in HCM is
primary ventricular tachycardia and/or ventricular
ﬁbrillation (27), with the application of ICDs to this
disease almost 15 years ago (27), has created the op-
portunity to prevent these catastrophic events for the
ﬁrst time. Therefore, the importance of risk stratiﬁ-
cation models to predict which individual patients
would beneﬁt most from device therapy has become
increasingly relevant.
Targeting candidates for prophylactic ICD therapy
can be complex, compounded by the unpredictability
of the arrhythmogenic substrate, absence of a single
dominant risk marker, and the impracticability of
prospective randomized trials (4,8,33,34,39,40).
Despite these limitations, the HCM risk stratiﬁcation
algorithm currently in use for primary prevention
has proved effective in identifying most patients
who will beneﬁt from ICD therapy by relying largely
on 5 major risk markers (4,6,8,39,40,65,76,77) (Fig. 3).
Although multiple risk factors in a given patient
intuitively convey the greatest SD risk, there is
compelling evidence that a single strong marker
within the clinical proﬁle of an individual patient
(particularly in those <60 years of age) can be sufﬁ-
cient evidence to raise the option of a primary pre-
vention ICD (8,28,40). These decisions are made in
accord with the wishes of the fully informed patient
after considering the beneﬁts as well as the inherent
possibility of device complications, including inap-
propriate shocks. Furthermore, strong desires of
informed patients can contribute to resolution of
ambiguous ICD decisions when the data are insufﬁ-
cient (including some involving a single risk marker);
these decisions also rely on the experience and
judgment of individual clinicians who adjudicate the
overall risk proﬁle (28).
Of note, the risk prediction model used in adult
HCM patients is not easily translated to children,
although a marked degree of LVH or syncope have
proved the most reliable markers in this age group
(29). Some investigators have stratiﬁed the likelihood
of SD by simple arithmetic summing of risk factors,
or sophisticated mathematical modeling. These ap-
proaches still require broad-based validation (20,32).
Because HCM encompasses a particularly diverse
spectrum, other small high-risk patient subsets
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91(i.e., LV apical aneurysms [19] with regional scarring
or end-stage with LV systolic dysfunction) (18) may
justify consideration for primary prevention ICDs
(Fig. 3). Disease features, such as marked LV outﬂow
obstruction at rest or diffuse LVH with wall thickness
approaching 30 mm (27,32,33), can serve as “gray zone
modiﬁers” or arbitrators for ICD decision making on a
case-by-case basis when assessment is ambiguous
using conventional markers. Engagement in intense
competitive sports is a modiﬁable SD risk factor, even
in the absence of other markers, leading to disquali-
ﬁcation to reduce risk, as recommended by Bethesda
Conference #36 (57).
Notably, the absence of all risk factors does not
convey immunity to SD in HCM (77). The present risk
model used in HCM is incomplete, as evidenced by
infrequent SD events in diagnosed patients judged to
be at low risk and ineligible for ICDs on the basis of
the absence of conventional markers (approximately
0.5%/year) (77). Recognition that seemingly low-risk
patients may nevertheless die suddenly underscores
the necessity to identify additional markers and/or a
single quantitative risk marker (similar to ejection
fraction in CAD).
These considerations have recently led to identiﬁ-
cation of a novel primary risk predictor (and arbi-
trator) in HCM (35). Contrast-enhanced CMR provides
an opportunity to image the substrate of presumed
myocardial ﬁbrosis. Because late gadolinium
enhancement (LGE) is so common in HCM, occurring
in >50% of patients, its presence alone is insufﬁcient
to risk stratify individual patients for SD. However,
absence of LGE is associated with a lower risk of SD
and represents a source of reassurance (35).
Conversely, SD risk is proportional to the amount
of LGE, with $15% (of LV mass) equivalent to a 2-fold
risk compared to patients without LGE (35). Extensive
LGE is a marker of SD risk, even among patients
otherwise considered at low risk and who do not have
established markers, but nevertheless can beneﬁt
from primary prevention ICD therapy (35).
In addition, results of contrast-enhanced CMR can
resolve complex ICD decisions when the level of SD
risk remains uncertain after standard stratiﬁcation;
that is, supporting an ICD when extensive LGE is
present and constituting evidence against an ICD
when LGE is absent or focal (35). Extensive LGE
also prospectively identiﬁes HCM patients who will
develop adverse LV remodeling and progress to the
end stage with systolic dysfunction (35). Therefore,
CMR has emerged as a powerful addition to the
HCM armamentarium, justifying a role in routine
assessment of these patients by strengthening the
risk stratiﬁcation model. However, drug treatmentwith aldosterone inhibitors (i.e., spironolactone) does
not appear to blunt development or progression of
myocardial ﬁbrosis in HCM (78).
IMPACT OF ICD IN PREVENTION OF SD
There is no evidence that drugs administered pro-
phylactically (e.g., beta-blockers or verapamil) pre-
vent SD in HCM (27–31). The ICD is the only
treatment strategy shown to prolong life in HCM
due to its potential to reliably interrupt life-
threatening ventricular tachyarrhythmias, and pre-
vent sudden and unexpected death (4,27–31,39,40)
(Central Illustration). In HCM, the ICD is effective
despite substantial LVH, outﬂow obstruction, dia-
stolic dysfunction, and microvascular ischemia
(4,9,11,16,21,36,62,65,79,80).
Much of the available data on ICDs comes from an
international multicenter registry of >500 HCM
patients, in which the rate of device interventions
appropriately terminating ventricular tachycardia
and/or ventricular ﬁbrillation was 4%/year for pri-
mary prevention (cumulative, 25% over 5 years),
largely in asymptomatic patients, and 11%/year
for secondary prevention after cardiac arrest (28)
(Fig. 3). These effective rates are similar to those re-
ported from numerous other centers in Europe,
Australia, and the United States (30,31,34). Further-
more, deﬁbrillator intervention rates were similar in
>200 children and/or adolescents with HCM who
underwent implantation for primary or secondary
prevention at <20 years of age (29). An exception to
ICD efﬁcacy is in LAMP2 patients, who are usually
refractory to deﬁbrillation (55).
In HCM, the unpredictability of the electrical
myocardial substrate is substantial, and relevant to
the principle of ICD therapy. First, there is extensive
variability in the time intervals between recognition
of high-risk status at implantation and the initial
appropriate ICD intervention, with delays of 5 to 10
years or even longer reported (28). Also, some HCM
patients have survived 10 to 20 years (up to 30 years)
after cardiac arrest without a subsequent event (81).
Second, ICD shocks occur randomly during the day
without deﬁned circadian periodicity, often unasso-
ciated with physical activity and sometimes during
sleep (82). Third, there is a relationship between pa-
tient age and susceptibility to ICD interventions:
uncommon after 60 years of age (38), but on average
occur at about 40 years of age on average (28).
The importance of device-related complications
(5%/year), including inappropriate shocks, lead de-
fects (83), and psychosocial consequences, cannot be
underestimated in HCM (27,28,31,84), particularly
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derscores the importance of balancing preservation of
life versus the possibility of device-related compli-
cations over time. Single-chamber ICDs are most
appropriate for young high-risk patients, whereas
dual-chamber ICDs are largely reserved for those with
paroxysmal AF and/or LV outﬂow obstruction (85).
Because subcutaneous deﬁbrillators are untested in
HCM, caution is warranted in considering implanta-
tion in patients with this disease (86).
ATHLETES
HCM is the most common cause of SD in the young,
including competitive athletes (44,87). About
one-third of athletic ﬁeld deaths in U.S. high school
and college students engaged in organized sports are
due to HCM (15/year) (87), occurring predominantly
in males without previous suspicion of disease, and
most commonly in African Americans (44). These SD
events provide a window to the population of HCM
patients who otherwise are unrecognized and not
part of clinical cohorts or the literature.
In the United States, cardiovascular screening ini-
tiatives to identify such at-risk student athletes
customarily include a history and physical examina-
tion, although some screening programs in colleges
have utilized 12-lead ECGs with limited success in
identifying HCM (88). The American Heart Associa-
tion/American College of Cardiology (AHA/ACC) do
not recommend a national mandatory cardiovascular
screening program (88), partly because it is unre-
solved whether pre-participation ECG screening re-
duces HCM mortality in young athletes. Measures for
prevention of SD in athletes with HCM include wider
dissemination of automatic external deﬁbrillators for
secondary prevention and disqualiﬁcation from sports
competition, according to Bethesda Conference #36
recommendations (54).
HEART FAILURE
Some degree of HF occurs in approximately 50% of
HCM patients, expressed clinically as exertional dys-
pnea due to a variety of mechanisms, in the presence
of preserved systolic function (89). However, it is
rarely associated with clinical manifestations charac-
teristic of ischemic and nonischemic cardiomyopa-
thies (e.g., volume overload) (4). Such symptoms can
be accompanied by chest pain (atypical or typical of
atherosclerotic CAD), which are likely related to
microvascular ischemia (79,80). Chest pain in HCM
may also present as an independent clinical syndrome
in which management becomes challenging, althoughanecdotal evidence favors verapamil for achieving
symptom beneﬁt.
The most important cause of limiting HF symptoms
in HCM is mechanical impedance to LV outﬂow, usu-
ally due to systolic anterior motion of the mitral valve,
with gradients of $30 mm Hg an independent deter-
minant of progressive HF symptoms and HF or stroke
death (21) (Fig. 4). Outﬂow gradients are characteris-
tically dynamic, with spontaneous variability inﬂu-
enced by altered myocardial contractility and loading
conditions (2,4,11,16,21,39,40).
For patients without obstruction at rest, exercise
(stress) echocardiography is the preferred method for
provoking physiological gradients (16). Exercise-
induced outﬂow gradients ($30 mm Hg) identify
patients at greater risk for future symptomatic
progression, and thereby the possibility of septal
reduction intervention (Central Illustration, Fig. 4).
Nonphysiological provocation with pharmacological
agents (i.e., amyl nitrite or isoproterenol) or the Val-
salva maneuver are alternative methods for provok-
ing subaortic gradients, although these maneuvers
may not always reliably mimic the hemodynamics
responsible for symptoms during daily physical ac-
tivities. Cardiac catheterization may occasionally be
necessary to resolve ambiguity with respect to pres-
ence and/or magnitude of gradients. In HCM, impor-
tant HF symptoms are also produced by impaired
diastolic ﬁlling or AF (90–93).
HEART FAILURE WITH OBSTRUCTION. Medica l
t reatment . In HCM patients with outﬂow tract
obstruction who develop limiting HF symptoms, the
ﬁrst option to control symptoms is pharmacological
therapy with beta-adrenergic blockers (4–6,39,40,94)
(Central Illustration). Although verapamil can also be
considered, caution should be exercised in its
administration to patients with marked resting gra-
dients and advanced HF. LV ﬁlling can be improved
by these drugs, although basal gradients are not
usually mitigated signiﬁcantly (4,39,40).
Beta-blockers are most effective in blunting gradi-
ents provoked with exercise (2,94). Disopyramide is
the most reliable drug for reducing outﬂow gradients
at rest in HCM, although long-term use may be
limited by parasympathetic side effects (95). Current
pharmacological therapy for HCM does not alter
outcome or phenotypic expression. However, a
number of novel drug therapies are currently being
considered for testing to improve the limiting symp-
toms of HCM by targeting speciﬁc disease-related
mechanisms (96).
Invas ive therapy . Because of the duration of expe-
rience, documented long-term results, and safety
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FIGURE 4 Clinical Signiﬁcance and Implications of LV Outﬂow Tract Obstruction
(A) Patients with outﬂow gradients $30 mm Hg at rest are at greater risk for HCM-related progressive heart failure, or heart failure or stroke
death. Adapted with permission from Maron et al. (21). (B) Abolition of LV outﬂow gradient by surgical septal myectomy is associated with
long-term survival (with respect to all-cause mortality) similar to expected in age- and sex-matched general U.S. population, and exceeding
that in a comparison group of symptomatic nonoperated patients with obstruction. Adapted with permission from Ommen et al. (36). (C) Most
HCM patients (i.e., 70%) have LV outﬂow obstruction present at rest or with physiologic exercise. Some patients with only exercise-provoked
gradients develop marked heart failure symptoms and also become candidates for septal reduction. Adapted with permission from Maron et al.
(16). (D) Different morphologic consequences of alcohol septal ablation (left) and surgical septal myectomy (right) shown with post-contrast
CMR images. Alcohol ablation results in a bright, dense transmural scar (arrow), whereas intramyocardial scarring is absent after myectomy.
Adapted with permission from Valeti et al. (106). NYHA ¼ New York Heart Association; RR ¼ relative risk; other abbreviations as in Figures 1 to 3.
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93data, surgical septal myectomy is considered the
preferred treatment for patients with advanced
limiting HF symptoms due to outﬂow gradients
of $50 mm Hg (at rest and/or with physiologic [ex-
ercise] provocation) who are refractory to maximal
medical management (4–6,10,13,36,39,40,97–100).
This is on the basis of the expert consensus guidelines
and recommendations from the ACC, AHA, and Eu-
ropean Society of Cardiology panels (39,40).
Long-term studies over 40 years inHCMhave shown
that surgicalmyectomy reliably reversesHF symptoms
by permanently abolishing obstruction, restoring
normal LV pressures, and reducing or abolishingmitral
regurgitation (4,10,40). Operative mortality for septal
myectomy is now <1% at experienced centers (10),
and the documented beneﬁts of myectomy providepatients with the opportunity to achieve good quality
of life, extended longevity, and survival similar to that
in the general population (36) (Fig. 4).
Percutaneous alcohol septal ablation has become
an alternative to surgical myectomy (37,101–105) in
selected patients (39,40). Factors that inﬂuence the
decision to proceed with alcohol ablation include
advanced age, signiﬁcant comorbidity that increases
surgical risk, or the strong desire of patients to avoid
open-heart surgery (40).
Alcohol ablation reduces LV outﬂow gradient (and
symptoms) by creating a large basal ventricular septal
infarction (10% of the LV wall, 30% of the septum, on
average) by infusion of absolute alcohol into a major
septal perforator coronary artery (106) (Fig. 4). In
contrast, myectomy requires resection of a small
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94amount of muscle from the basal septum, but without
intramyocardial scarring (10,39,40). Ablation data
derived from some retrospective studies show short-
term survival (with respect to all-causemortality) to be
similar to myectomy and in also age- and sex-matched
general populations. Procedural mortality, low in
experiencedmyectomy programs (4,10,13,36,39,40), is
similar for both interventions when performed at HCM
centers (37).
However, important differences between the septal
reduction procedures have emerged over 2 decades,
with surgery providing better symptom and gradient
improvement in patients<65 years of age. Surgery also
provides the opportunity to address complex LV
morphologic abnormalities that may contribute to
outﬂow obstruction: papillary muscle anomalies and
aberrant intraventricular muscle bundles; massive
septal hypertrophy; intrinsic mitral valve disease
(requiring repair or replacement); and associated CAD
that requires bypass grafting (10,37,40).
In contrast, alcohol ablation is associated with the
likelihood of permanent pacemaker implantation for
complete heart block (in 10% to 15% of patients) and
repeat procedures due to persistent obstruction (in
12% of patients) (101,104). There is an incompletely
deﬁned risk for life-threatening ventricular tachyar-
rhythmias and SD due to the potentially arrhythmo-
genic septal scar, which was reported as signiﬁcant in
3 single-center studies (102,103,105) and the Multi-
center North American Registry (107). No risk strati-
ﬁcation model for prophylactic ICD implantation
following ablation has been proposed.
Optimally, both myectomy and alcohol ablation
should be performed in multidisciplinary centers with
extensive HCM treatment experience and demon-
strable high success and low procedural mortality
rates, with the selection of either procedure balanced
and unbiased in accord with autonomy of the fully
informed patient (40). A randomized trial comparing
myectomy versus alcohol ablation is impractical and
unrealistic (108). Dual-chamber pacing was promoted
with enthusiasm in the 1990s as an alternative to sur-
gery (109), but it has been largely abandoned on the
basis of double-blind crossover trials that showed the
perceived symptomatic beneﬁt was largely a placebo
effect (110).
HEART FAILURE WITHOUT OBSTRUCTION. About
one-third of HCM patients have the nonobstructive
form with absent or small (<30 mm Hg) outﬂow gra-
dients at rest and with physiological exercise (16). The
majority of nonobstructive HCM patients experience
a relatively stable clinical course without signiﬁcant
symptoms, high-risk proﬁle, or the necessity of major
treatment options (111).Only a minority of nonobstructive patients will
experience progressive, limiting HF symptoms pre-
dominantly due to diastolic dysfunction (111) (Central
Illustration). Medical treatment is limited to atrio-
ventricular nodal blocking agents (and possibly low-
dose diuretics) that may exert a beneﬁcial effect on
diastolic function by increasing myocardial blood
ﬂow and LV ﬁlling time, but often without long-term
efﬁcacy. The clinical severity of diastolic dysfunction
in HCM is difﬁcult to assess directly because nonin-
vasive measures of diastolic function do not accu-
rately reﬂect LV ﬁlling pressures (112).
The most advanced form of HF within the HCM
spectrum is the end-stage (or “burned out”) phase
occurring in a distinctive subset of patients with
nonobstructive HCM (prevalence, 3%) (18). HF pro-
gression is associated with conversion to systolic
dysfunction (ejection fraction <50%) and adverse LV
remodeling with extensive myocardial scarring, often
resulting in regression of hypertrophy and/or cavity
enlargement (35,113). Initial treatment considerations
are beta-blockers, diuretics, and afterload reducing
agents, as well as prophylactic ICDs.
The clinical course of end-stage patients is variable
and unpredictable, but HF symptoms may progress
rapidly in some, suggesting the prudence of early
listing for transplantation. This remains the only
deﬁnitive therapeutic option for this relatively young
patient group (average age, 43 years) (18). Post-
transplantation survival (75% at 5 years; 60% at
10 years) is similar or possibly more favorable than
that for patients with other cardiac diseases (114). The
only known predictor of end-stage HCM is a family
history of end-stage disease. A small subset of non-
obstructive HCM patients with preserved systolic
function who develop refractory HF symptoms due to
diastolic dysfunction can also become heart trans-
plantation candidates.
ATRIAL FIBRILLATION
GENERAL CONSIDERATIONS. Although it is rarely
the initial manifestation of HCM, AF (or atrial ﬂutter)
represents the most common disease complication
and sustained arrhythmia, occurring in 25% of pa-
tients, which is 4-fold more common than in the
general population (90–93). Asymptomatic and clini-
cally silent periods of this arrhythmia are not un-
commonly detected by random ambulatory
monitoring. Most common are paroxysmal episodes,
although AF may become permanent over time in a
minority of patients.
Susceptibility to AF is linked to increasing age,
greater left atrial volume and/or impaired left atrial
FIGURE 5 Adverse Pathways Within the Broad HCM Clinical Spectrum
Individual patients may be subject to disease progression along 1 or more of these complication pathways, each of which is associated with
potentially effective treatment options. Alternatively, most HCM patients probably experience a benign course without requiring major in-
terventions. AF ¼ atrial ﬁbrillation; other abbreviations as in Figures 1 and 2.
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95ejection fraction (115). AF onset is at 55 years on
average, $10 years earlier than in the general popu-
lation, but is rare in children and young adults. AF
may not be well tolerated when associated with LV
outﬂow tract obstruction, and not uncommonly oc-
curs in patients with systolic dysfunction and
advanced HF (end-stage) (18,90).
AF and left atrial remodeling are inter-related and
independent predictors of adverse outcome in HCM
(90–93). Frequent paroxysmal AF episodes (or chronic
AF) may negatively impact quality of life, accounting
for unexpected hospital admission, lost work and
productivity, and is often associated with progressive
HF. The pattern of occurrence and the number of
symptomatic AF episodes are unpredictable and vary
considerably among individual patients. However,
whether infrequent AF reliably predicts unfavorable
long-term consequences is unresolved. Patients
with AF usually experience no or mild symptoms
while in sinus rhythm, unless associated LV outﬂow
obstruction is responsible for exertional dyspnea. No
clinically relevant relationship has been reported
between AF and SD (90).
MANAGEMENT. Relatively infrequent AF episodes are
effectively reversed by electrical or pharmacologi-
cal cardioversion (or resolve spontaneously), but oc-
casionally can trigger acute clinical decompensation.Low-dose amiodarone is generally regarded as the
most effective agent for reducing AF recurrences,
although it frequently has side effects that limit its use
over time, particularly in young patients. Alternative
antiarrhythmic drug therapy includes sotalol or
possibly disopyramide in the presence of obstruction.
HCM patients with AF have an increased risk of
thromboembolic stroke, 0.8%/year (91). Because of
the potential for clot formation in the enlarged left
atrium, stroke prevention is initiated by prophylactic
anticoagulation with warfarin or newer oral agents
(i.e., dabigatran or rivaroxaban), tailored to individ-
ual patients after consideration for lifestyle modiﬁ-
cations, hemorrhagic risk, and expectation for
compliance. An aggressive posture with a low
threshold for intervention with anticoagulation has
been recommended for all patients with symptomatic
AF episodes, given that the CHADS score is not spe-
ciﬁcally validated or useful in this disease.
When quality of life is signiﬁcantly affected by
frequent symptomatic AF episodes in drug-refractory
patients, the option of catheter-based ablation (radi-
ofrequency or cryoablation) has proved promising
(92,116,117). Although relatively early in its develop-
ment, catheter ablation provides the potential for
prolonged restoration of sinus rhythm, although the
selection of patients with the greatest likelihood of
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suggest that two-thirds of patients maintain sinus
rhythm for 3 years, although a substantial proportion
may require $2 procedures, with most continuing on
antiarrhythmic drugs and anticoagulation (116,117).
For severely symptomatic patients with outﬂow
obstruction and AF, combining myectomy with the
Maze procedure has been suggested, although the
efﬁcacy of this practice is unknown.
CONCLUSIONS
For many years, HCM was considered a rare and un-
usual condition, largely without effective manage-
ment strategies, and particularly devoid of treatment
options for SD risk. As cardiovascular medicine has
evolved over the last 2 decades (principally focused
on atherosclerotic CAD), advances in diagnosis and
management have been translated into genetic heart
diseases such as HCM. The efforts of many in-
vestigators in different parts of the world have more
precisely deﬁned the clinical and morphological
spectrum and natural history of HCM, and captured
its exceptional heterogeneity, complexity, and
unpredictability.
At this juncture, based on the effective use of ICDs
for primary prevention, heart transplantation for
refractory HF, advances in the surgical treatment of
outﬂow tract obstruction now associated with low
risk and excellent long-term outcome, and out-of-
hospital deﬁbrillation techniques (including thera-
peutic hypothermia) (118), it is appropriate to regard
the evolution of HCM in 2014 as a paradigm shift toa contemporary treatable disease (119) (Fig. 5). These
advances now provide a substantial proportion of
individuals affected by HCM with the opportunity
to achieve normal or extended life expectancy with-
out disability or the requirement for major treatment
interventions to achieve that outcome.
Although HCM deserves greater optimism from
the cardiovascular community than in previous eras,
it nevertheless remains a complex disease entity
with the need for continued focused investigation to
meet a number of future challenges. Although the
ICD is a proven measure for preservation of life in
HCM, the need to more precisely identify which
patients will beneﬁt from this therapy remains a
critical issue. Pharmacological therapy to control
symptoms of HF has remained unchanged over
many years and requires innovation to identify
novel agents tailored to HCM. Although the molec-
ular era has provided the opportunity to perform
rapid genetic testing to identify family members at
risk of developing HCM, the genetic substrate re-
mains unresolved for a substantial proportion of
patients. Finally, there is a need to better under-
stand the structural and metabolic derangements
caused by the pathogenic mutations to allow novel
therapies to be developed that target key pathways
of disease progression.
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